The 2018 Congress of the International Society of Hypertension in Pregnancy will take place in Amsterdam this year and Metabolomic Diagnostics will sponsor and present a poster at the event.  It will be a joint meeting with the International Society for Obstetric Medicine (ISOM) and will cover all aspects of research into hypertension in pregnancy.

The theme of this year’s meeting is: “Translational research in preeclampsia: Maternal and transgenerational effects”. The program covers the whole field of translational research with a multi-directional and multidisciplinary integration of basic research, patient-oriented research, and population-based research with the aim of improving the long-term health of women. Besides discussing developments of new treatments of hypertension and its complications during pregnancy, central themes are the understanding of the long-term consequences for future health for mother and child of placental disease and intrauterine deprivation as is often the case in preeclampsia and the risk of future cardiovascular disease for women suffering from hypertension and preeclampsia. Worldwide collaboration in translational research is the only way to be successful in improving the health of mother and child during and after preeclampsia.

Metabolomic Diagnostics will present a poster entitled:

“Combining Metabolite Biomarker and Placental Growth Factor Yields A Prognostic Test for Preterm Pre-eclampsia”

Thirteen prognostic metabolites have been identified following a comprehensive verification exercise. These metabolites are now progressed to a clinical assay for the prognosis of pre-eclampsia. 3 metabolite biomarkers were found to complement PIGF. Based on the data presented, accurate prediction of preterm pre-eclampsia at 15 weeks gestation is now also possible in a first-time pregnant patient group that were missed by screening protocols used in clinical practice.

The 2018 ISHPP conference will be held in The Westergasfabriek, Amsterdam, The Netherlands, October 7th to Oct 9th.